STAT Plus: AstraZeneca aims to carve into Merck’s immunotherapy dominance
KIRSTY WIGGLESWORTH/AP
New data in lung cancer will likely lead to speculation as to whether Merck can hold onto its dominance with its treatment, Keytruda.
Cambiar nuestra forma de vivir para cambiar el mundo
Hace 12 horas
.png)
No hay comentarios:
Publicar un comentario